| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Provides Greater Value than STAAR Could Achieve on a Standalone Basis in the Foreseeable Future and is the Best Path Forward for STAAR Stockholders
Files Definitive Proxy Materials and Mails Letter to STAAR Stockholders
Encourages Stockholders to Vote "FOR" the Value Maximizing Alcon Merger Today
STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it has filed its definitive proxy statement with the U.S. Securities and Exchange Commission in connection with the Company's pending merger with Alcon (NYSE:ALC). STAAR will hold a Special Meeting of Stockholders on October 23 at 8:30 a.m. (Pacific Time) to vote to adopt the merger agreement. Stockholders of record as of the close of business on September 12, 2025, are entitled to vote at the meeting.
In conjunction with the definitive proxy filing, STAAR is mailing the following letter to STAAR stockholders:
Dear Fellow Stockholders,
On August 5, 2025, we announced that STAAR Surgical Company entered into a definitive merger agreement to be acquired by Alcon for $28.00 per share in cash. STAAR will hold a virtual Special Meeting of Stockholders on October 23 at 8:30 a.m. (Pacific Time) to ask for your vote to adopt the merger agreement. The STAAR Board of Directors unanimously determined that the proposed merger with Alcon is in the best interests of STAAR and its stockholders and strongly recommends that you vote "FOR" the merger proposal, as described in the accompanying proxy statement.
$28.00 per share is a compelling premium on multiple measures:
~51% Premium to closing stock price day prior to announcement | ~59% Premium to 90-day VWAP | Significantly Higher Premium compared to the 26% median for comparable MedTech transactions | 47% Premium to median sell-side price targets prior to merger announcement |
